The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9902947 B1

PDF
Full Text
Expired
Date of Patent:
Feb. 27, 2018

Filed:

Jan. 24, 2012
Applicants:

Michael Esquerré, Toulouse, FR;

Marie Momot, Toulouse, FR;

Anne Goubier, Sauveterre de Bearn, FR;

Yolande Misseri, Dremil-Lafage, FR;

Inventors:

Michael Esquerré, Toulouse, FR;

Marie Momot, Toulouse, FR;

Anne Goubier, Sauveterre de Bearn, FR;

Yolande Misseri, Dremil-Lafage, FR;

Assignee:

GENTICEL, Labege, FR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 9/88 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/39 (2006.01);
U.S. Cl.
CPC ...
C12N 9/88 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/39 (2013.01); A61K 2039/55511 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/585 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/70 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C12N 2710/20034 (2013.01);
Abstract

The invention is directed to means, based on CyaA-carried polypeptide(s), for use in the immunotherapeutic treatment of first determined pathological condition(s) diagnosed in a mammalian host by eliciting a T cell immune response against a first group of epitopes contained in said polypeptide(s) and in the prophylaxis against second determined pathological condition(s) in the same mammalian host by eliciting a T cell memory immune response against a second group of epitopes contained in said polypeptide(s), said immune responses being obtained after administration of said vector-carried polypeptide(s) into said host, wherein said prophylaxis against second determined pathological condition(s) is not observed when said second group of epitopes is not contained in said administered vector-carried polypeptide(s).


Find Patent Forward Citations

Loading…